In the prehospital setting, what are the indications and benefits of intravenous magnesium sulfate for severe asthma, chronic obstructive pulmonary disease (COPD), torsades de pointes, prolonged QT interval, eclampsia, and severe pre‑eclampsia?

Prehospital Magnesium Sulfate: Indications and Benefits

In the prehospital setting, intravenous magnesium sulfate should be administered for severe/life-threatening asthma exacerbations unresponsive to initial bronchodilators, torsades de pointes with prolonged QT, and severe pre-eclampsia/eclampsia with seizures or imminent seizure risk, but has no established role for COPD exacerbations or routine QT prolongation without torsades.

Severe Asthma Exacerbations

Magnesium sulfate is indicated for life-threatening asthma or severe exacerbations that remain critical after 1 hour of intensive conventional treatment 1. The evidence shows no benefit in mild-to-moderate exacerbations, but significant improvement in severe cases.

When to Administer:

• Signs of impending respiratory failure: inability to speak, altered mental status, intercostal retractions, worsening fatigue, PaCO2 ≥42 mm Hg 1
• FEV1 <25% predicted after initial bronchodilator therapy 2
• Life-threatening presentation despite standard therapy (beta-agonists and corticosteroids) 3

Dosing and Administration:

• Standard adult dose: 2 g IV over 20 minutes 3
• Must be diluted to ≤20% concentration 4
• Rate should not exceed 150 mg/minute except in severe eclampsia 4

Evidence of Benefit:

A Cochrane meta-analysis demonstrated that IV magnesium sulfate improves pulmonary function and reduces hospital admissions, particularly in the most severe exacerbations 3. In patients with initial FEV1 <25% predicted, magnesium produced a 9.7% improvement in final FEV1 compared to placebo (p=0.001) 2. The mechanism is relaxation of bronchial smooth muscle independent of serum magnesium levels, with only minor side effects (flushing, light-headedness) 3.

Critical Caveat:

Do not delay intubation if deemed necessary 1. Magnesium is an adjunct attempted while preparing for intubation in severely ill patients, not a substitute for definitive airway management.

COPD Exacerbations

Magnesium sulfate has no established role in prehospital COPD management and should not be routinely administered. While recent research suggests possible benefit in acute COPD exacerbations, the evidence remains insufficient and of very low certainty 5, 6.

The 2022 Cochrane review found that magnesium may reduce hospital admissions and improve dyspnea in COPD exacerbations, but concluded that "we are unable to draw conclusions about its effects in COPD exacerbations for most outcomes" due to very low-certainty evidence 6. This contrasts sharply with the established benefit in severe asthma. In the prehospital setting, focus on standard COPD therapies (bronchodilators, corticosteroids, oxygen titration) rather than magnesium.

Torsades de Pointes and Prolonged QT

Magnesium sulfate is the first-line treatment for torsades de pointes associated with acquired QT prolongation 7, 8, 9.

Clear Indications:

• Recurrent torsades de pointes with acquired QT prolongation (Class I recommendation) 7
• Episodes of torsades-type VT with prolonged QT interval 10
• Drug-induced QT prolongation with torsades 8, 9

Dosing:

• 1-2 g IV bolus over 5 minutes 10, 11
• Can repeat doses as needed to suppress ectopy 7
• For recurrent episodes: may require continuous infusion or temporary pacing 7

Mechanism and Efficacy:

Magnesium suppresses torsades episodes without necessarily shortening QT, even when serum magnesium is normal 7, 9. It works by stabilizing cardiac membranes and reducing triggered activity. Magnesium is NOT likely to be effective in patients with normal QT intervals 8.

Additional Management:

• Correct hypokalemia: maintain potassium 4.5-5.0 mEq/L 7, 9
• Correct hypomagnesemia: maintain magnesium ≥2.0 mmol/L 7
• If recurrent despite magnesium: increase heart rate with temporary pacing or isoproterenol 7, 8

Important Distinction:

For prolonged QT WITHOUT torsades: Magnesium is reasonable for medication-induced QT prolongation as prophylaxis 10, 11, but the primary intervention is removing the offending agent and correcting electrolytes. Do not routinely give magnesium for isolated QT prolongation without arrhythmia.

Eclampsia and Severe Pre-eclampsia

Magnesium sulfate is the definitive treatment for eclamptic seizures and prevention of seizures in severe pre-eclampsia 12, 4.

Indications in Prehospital Setting:

• Active eclamptic seizures (Class I) 4
• Severe pre-eclampsia with clinical signs of severity: hyperreflexia, frontal headache, blurred vision, epigastric tenderness 12, 13
• Any pre-eclamptic patient with imminent seizure risk during transport 12

Dosing for Eclampsia/Severe Pre-eclampsia:

Loading dose: 4-5 g IV over 3-4 minutes 4

• Can give simultaneously with IM doses (5 g in each buttock = 10 g IM total) for total initial dose of 14 g 4
• Maintenance: 1-2 g/hour continuous IV infusion 4
• Target serum level: 6 mg/100 mL for seizure control 4

Critical Safety Monitoring:

• Check patellar reflexes - loss indicates toxicity 4
• Monitor respiratory rate - must remain adequate 4
• Urine output monitoring - magnesium is renally excreted 13
• Maximum dose: 30-40 g/24 hours (20 g/48 hours in severe renal insufficiency) 4

Duration:

• Continue until paroxysms cease 4
• Typically 24 hours postpartum or 24 hours after last seizure 13
• Do NOT exceed 5-7 days continuous use in pregnancy - can cause fetal abnormalities 4

Evidence Base:

Magnesium sulfate is superior to other anticonvulsants for reducing recurrent convulsions in eclampsia 14. It reduces eclampsia incidence in severe pre-eclampsia, though routine use in all pre-eclampsia cases is not justified given lower seizure risk in mild disease 13.

Toxicity Recognition and Management

Signs of Magnesium Toxicity:

• Loss of patellar reflexes (first sign)
• Respiratory depression
• Areflexia progressing to respiratory arrest 7, 9
• Occurs at serum concentrations 6-8 mEq/L 9

Antidote:

Calcium gluconate or calcium chloride - have immediately available when administering magnesium 13

Key Contraindications

• Myasthenia gravis - can precipitate crisis
• Heart block - except when treating torsades 10
• Severe renal failure - reduce dose significantly 4
• Hypotension - relative contraindication, monitor closely

Summary Algorithm for Prehospital Use

Give magnesium sulfate 2 g IV if:

1. Severe asthma with impending respiratory failure after initial bronchodilators
2. Torsades de pointes with prolonged QT
3. Eclamptic seizures or severe pre-eclampsia with imminent seizure risk (4-5 g loading dose)

Do NOT give magnesium for:

• Mild-moderate asthma
• COPD exacerbations (insufficient evidence)
• Isolated QT prolongation without torsades
• Mild pre-eclampsia without severe features